Small BusinessGlenmark Pharma to repay Rs 300 cr debt by fiscal end
Pharma major Glenmark Pharmaceuticals is planning to repay its debt of around Rs 300 crore by end of this fiscal, a top company official said.
- Dubai World mulls 4 options for repaying debt - Emaar MGF says no impact of Dubai crisis - Medicis takes Lupin to US court on patent charge - Glenmark, Medicis sign two agreements - Glenmark settles patent dispute with Medicis - Glenmark Generics gets US FDA nod for Ciclopirox Olamine
"We will repay our debt of around Rs 300 crore during the third or fourth quarter of this financial year," Glenmark"s Chief Executive Officer and Managing Director Glenn Saldanha told reporters on the sidelines of a pharma summit here today.
The company"s present debt is around Rs 1,650 crore, he said.
Its generic arm--Glenmark Generics, plans to raise around Rs 575 crore through an IPO by end of this fiscal, he said.
"We are looking at Rs 575 crore through an IPO by our generics arm," Saldhana said, adding that the company has already filed its draft red hearing prospectus.
The proceeds of the IPO will go towards repayment of our debts," he added.
Glenmark Generics has recently received ANDA (Abbreviated New Drug Application) approval from the US Food and Drug Administration for Ciclopirox Olamini cream used in the treatment of dermatological infection, he said.
"The company will start marketing and distribution of the product in the US," he said.